OPKO Health’s weekly growth hormone injection could be approvable in adults without need for further clinical trials, the company has told pharmaphorum. The biotech has worked with Pfizer to co ...

In December 2014, Pfizer and OPKO began an agreement to develop hGH-CTP for growth hormone deficiency in adults and children, and for children who are small for gestational age and fail to show ...

The market supports treatment for growth hormone deficiencies and anti-aging therapies. Biosimilar development enhances accessibility. Human Growth Hormone Market report furnishes invaluable ...

While Pfizer COVID vaccine is known to have multiple side effects, many women have been complaining of enlarged breasts.

The game-changing drugs, which mimic the hormone GLP-1, offer large benefits ... promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw ...

Additionally, Pfizer’s strategic focus on obesity treatments, despite cautious expectations for danuglipron, remains a significant growth area. The company’s robust acquisitions strategy ...

Further, Pfizer's Q3 adjusted diluted EPS of $1.06 beat street estimates by 45 cents reflecting the translation of top-line growth into bottom-line gains larger than expected. This performance was ...

With over two decades in breast cancer research and patient support, Pfizer believes ... especially for patients with hormone receptor-positive (HR +)/human epidermal growth factor receptor ...

Pfizer said Tuesday. The company also cited sales growth from several other drugs, as total revenue climbed 31% to $17.7 billion in the recently completed quarter. Adjusted earnings totaled $1.06 ...

Pfizer expects 2025 adjusted EPS to be in a range of $2.80 to $3.00, reflecting expected operational growth of 10% to 18%, year-over-year, from the midpoint of 2024 baseline guidance. Pfizer ...